Evonik Develops Polymer Technology To Enable Bonding With Fluoropolymers
Innovative Material Streamlines Catheter Manufacturing Process
Evonik Corporation has developed a new polymer technology which adheres directly to Daikin America, Inc.’s modified fluorinated ethylene-propylene copolymer (EFEP). The complementary properties of the two materials greatly improve catheter quality and reliability while reducing manufacturing costs through co-extrusion.
“These two material technologies allow for a more efficient manufacturing process, not only creating a very strong bond between the two polymers, but also saving manufacturing costs,” said Sabine Fleming, Business Development Manager, High Performance Polymers business line. “By using Evonik’s VESTAMID® Care modified polyether block amide (PEBA) and Daikin’s NEOFLON™ modified fluorinated ethylene-propylene copolymer (EFEP), the two materials can be co-extruded into a very robust tubing construction that requires no toxic etching compound, does not delaminate and is highly reliable.”
This polymer technology enables manufacturers to produce PEBA/EFEP-based medical devices including catheters and surgical tubing, and will debut at the 2014 MD&M West trade show in Anaheim, Ca., on February 11.
“Evonik and Daikin are very excited to offer these complementary technologies to the medical device market,” said John Felton, market development manager at Daikin. “Original equipment manufacturers (OEMs) now have the ability to combine the excellent properties of PEBA and EFEP through a streamlined manufacturing process that is easier and more reliable than traditional methods.”
Evonik’s booth at MD&M West is #2330 and Daikin’s is #973.
For additional information about Evonik in North America, please visit our website: www.evonik.com/north-america. Please visit us on Facebook at www.facebook.com/EvonikNorthAmerica. Follow us on Twitter at http://twitter.com/EvonikN_America.
Evonik, the creative industrial group from Germany, is one of the world leaders in specialty chemicals. Profitable growth and a sustained increase in the value of the company form the heart of Evonik’s corporate strategy. Its activities focus on the key megatrends health, nutrition, resource efficiency and globalization. Evonik benefits specifically from its innovative prowess and integrated technology platforms.
Evonik is active in over 100 countries around the world. In fiscal 2012 more than 33,000 employees generated sales of around €13.4 billion and an operating profit (adjusted EBITDA) of about €2.4 billion (excluding Real Estate in both cases).
In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.